OrthoPediatrics (FRA:2X7) Cyclically Adjusted Revenue per Share: €6.32 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2X7 OrthoPediatrics Corp FRA:2X7
79 GF Score
Price €16.10
GF Value €28.70
! 5 Warning Signs
View Full Analysis

What is OrthoPediatrics Cyclically Adjusted Revenue per Share?

OrthoPediatrics FRA:2X7 -1.23% 79 Cyclically Adjusted Revenue per Share is €6.32 as of Mar. 2026. GuruFocus rates FRA:2X7 with a GF Score™ of 79/100 and a GF Value™ of €28.70. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

OrthoPediatrics's adjusted revenue per share for the three months ended in Mar. 2026 was €2.168. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €6.32 for the trailing ten years ended in Mar. 2026.

During the past 12 months, OrthoPediatrics's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-22), OrthoPediatrics's current stock price is €16.10. OrthoPediatrics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €6.32. OrthoPediatrics's Cyclically Adjusted PS Ratio of today is 2.55.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of OrthoPediatrics was 3.27. The lowest was 2.03. And the median was 2.48.


OrthoPediatrics  (FRA:2X7) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

OrthoPediatrics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.10/6.32
=2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of OrthoPediatrics was 3.27. The lowest was 2.03. And the median was 2.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


OrthoPediatrics Cyclically Adjusted Revenue per Share Related Terms


OrthoPediatrics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for OrthoPediatrics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OrthoPediatrics Cyclically Adjusted Revenue per Share Chart

OrthoPediatrics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 6.23

OrthoPediatrics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.54 6.08 6.20 6.23 6.32

FRA:2X7 vs PACB, CLPT, MOBI: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, OrthoPediatrics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OrthoPediatrics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OrthoPediatrics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where OrthoPediatrics's Cyclically Adjusted PS Ratio falls into.


FRA:2X7
79GF Score
OrthoPediatrics Corp FRA:2X7
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OrthoPediatrics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, OrthoPediatrics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.168/330.2130*330.2130
=2.168

Current CPI (Mar. 2026) = 330.2130.

OrthoPediatrics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.146 241.018 1.570
201609 1.202 241.428 1.644
201612 1.188 241.432 1.625
201703 5.233 243.801 7.088
201706 1.398 244.955 1.885
201709 0.862 246.819 1.153
201712 0.782 246.524 1.047
201803 0.812 249.554 1.074
201806 1.028 251.989 1.347
201809 1.074 252.439 1.405
201812 0.984 251.233 1.293
201903 0.903 254.202 1.173
201906 1.115 256.143 1.437
201909 1.287 256.759 1.655
201912 1.134 256.974 1.457
202003 0.901 258.115 1.153
202006 0.688 257.797 0.881
202009 0.986 260.280 1.251
202012 0.813 260.474 1.031
202103 0.939 264.877 1.171
202106 1.149 271.696 1.396
202109 1.105 274.310 1.330
202112 1.138 278.802 1.348
202203 1.098 287.504 1.261
202206 1.574 296.311 1.754
202209 1.658 296.808 1.845
202212 1.399 296.797 1.557
202303 1.311 301.836 1.434
202306 1.608 305.109 1.740
202309 1.645 307.789 1.765
202312 1.515 306.746 1.631
202403 1.801 312.332 1.904
202406 2.119 314.175 2.227
202409 2.122 315.301 2.222
202412 2.171 315.605 2.271
202503 2.087 319.799 2.155
202506 2.257 322.561 2.311
202509 2.214 324.800 2.251
202512 2.231 324.054 2.273
202603 2.168 330.213 2.168

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €6.32 mean?
OrthoPediatrics (FRA:2X7) has a Cyclically Adjusted Revenue per Share of €6.32 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on OrthoPediatrics and its competitors.
Is OrthoPediatrics' Cyclically Adjusted Revenue per Share too high?
OrthoPediatrics' current Cyclically Adjusted Revenue per Share is €6.32. Overall, OrthoPediatrics has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does OrthoPediatrics' Cyclically Adjusted Revenue per Share compare to PACB and CLPT?
OrthoPediatrics' Cyclically Adjusted Revenue per Share of €6.32 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on OrthoPediatrics and its competitors. OrthoPediatrics's current Cyclically Adjusted Revenue per Share is €6.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrthoPediatrics stock overvalued right now?
OrthoPediatrics (FRA:2X7) has a current Cyclically Adjusted Revenue per Share of €6.32. The stock's GF Value™ is €28.70, compared to a current price of €16.10 — trading 43.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €6.32. OrthoPediatrics' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For OrthoPediatrics (FRA:2X7), the current Cyclically Adjusted Revenue per Share is €6.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OrthoPediatrics (FRA:2X7) Overvalued in 2026?

Based on GuruFocus' analysis, OrthoPediatrics stock appears to be undervalued. The current stock price of €16.10 is trading 43.9% below its estimated GF Value™ of €28.70.

Key valuation signals for FRA:2X7:

  • Cyclically Adjusted Revenue per Share: €6.32
  • GF Value™: €28.70 vs. price of €16.10 (43.9% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the FRA:2X7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OrthoPediatrics Business Description

Other Exchanges KIDS:USA
Address 2850 Frontier Drive, Warsaw, IN, USA, 46582
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
79GF Score

Get the complete analysis for FRA:2X7

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.10
Price
€28.70
GF Value